2:52 PM
 | 
May 01, 2019
 |  BC Extra  |  Company News

May 1 Company Quick Takes: Heron, Nabriva, Allergan, GSK, Merck, Alnylam

Complete response letter for Heron’s non-opioid pain therapy
Heron Therapeutics Inc. (NASDAQ:HRTX) was off $3.93 (18%) to $17.75 on Wednesday after FDA issued a complete response letter for an NDA for HTX-011 to manage postoperative pain. The agency requested additional CMC and non-clinical information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam. Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX), which markets extended-release Exparel bupivacaine for postoperative pain, appeared to benefit from the news, gaining $6.43 (16%)...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >